AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02516267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiplate ADP®
Description: Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG
Study NCT01591850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: Single oral dose
Study NCT01591850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: Multiple oral doses
Study NCT01591850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Multiple oral doses
Study NCT01591850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Multiple oral doses
Study NCT01591850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Multiple oral doses
Study NCT04387656 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04387656 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Undergo collection of medical information and imaging
Study NCT04387656 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires
Study NCT04387656 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete quality of life questionnaires
Study NCT01960751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neurocognitive tests battery
Description: The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
Study NCT03795298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Implant
Description: Left atrial appendage closure with the WATCHMAN FLX device
Study NCT03795298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Market-approved OAC
Description: Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Study NCT01208051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT01208051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT01208051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01208051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT04197960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use thermal energy to destroy tumor
Study NCT04197960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Resect tumors
Study NCT03184675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional action observation training
Description: the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
Study NCT03184675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General action observation training
Description: step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC chemotherapy
Description: Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC chemotherapy
Description: Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's choice
Description: Physician decided chemotherapy for 0-4 cycles.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice
Description: Physician decided chemotherapy for 0-4 cycles.
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
Study NCT04398914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
Study NCT04398914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT04398914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT00582829 — intervention group
Intervention type: OTHER
Intervention: Generic Print Intervention
Description: Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant.
Study NCT00582829 — intervention group
Intervention type: OTHER
Intervention: Tailored Print Intervention
Description: Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
Study NCT00582829 — intervention group
Intervention type: OTHER
Intervention: Tailored print plus tailored phone intervention
Description: Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
Study NCT03439514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797 (PF-07265803)
Description: 400 mg twice daily (BID)
Study NCT03439514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID
Study NCT03769974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Two series of 30 seconds training of motor imagery in each manual engine gesture
Study NCT03769974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Two series of 30 seconds training of action observation training in video format in each manual engine gesture
Study NCT03769974 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
Study NCT05080270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Fibroblasts
Description: administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
Study NCT04383015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise strategies
Description: Strategies for exercise in type 1 diabetes to maintain glucose control
Study NCT00326495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
Study NCT00326495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
Study NCT03279419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal imaging
Description: Use of thermal imaging camera to capture images of peripheral vasculature (hands).
Study NCT04387214 — intervention group
Intervention type: OTHER
Intervention: survey
Description: online survey
Study NCT01629862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
Study NCT01629862 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous positive airway pressure
Description: CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab was administered as per schedule described in respective arm.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab was administered as per schedule described in respective arm.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered as per schedule described in the arms.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered as per schedule described in the arms.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin was administered as per schedule described in the arms.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin was administered as per schedule described in the arms.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as per schedule described in the arms.
Study NCT00676039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celexa
Description: Celexa 40 mg (Lundbeck, Brand Name)
Study NCT04526587 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
Study NCT04526587 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as per schedule described in the arms.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
Study NCT03197935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
Study NCT03278145 — intervention group
Intervention type: GENETIC
Intervention: Genetic analyses
Description: Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
Study NCT02797535 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy procedures
Description: GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
Study NCT03874403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DSA
Description: The changes on DSA on NIVATS and VATS
Study NCT03874403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA
Description: The changes on DSA on NIVATS and VATS
Study NCT04286958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
Study NCT01028053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutemetamol (18F) Injection
Description: All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
Study NCT02632214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI measure
Study NCT02632214 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: fMRI measure
Study NCT03346512 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Cardiac surgery
Study NCT02549378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal microscopy
Description: microvessel diameter measured by confocal microscopy
Study NCT02537925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg bid po, to the end of concurrent radiotherapy
Study NCT02537925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
Study NCT02537925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: 40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
Study NCT02537925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Radiotherapy
Description: The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
Study NCT02537925 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Radiotherapy
Description: The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample for serum and plasma biomarkers:
Description: Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample for biomarkers
Description: Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac bio-impedance (Cardioscreen Medis)
Description: Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)
Description: Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort.
Study NCT03376009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (Spectralis OCT)
Description: OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes.